Moxifloxacin Olikla (Moxifloxacin Hydrochloride)

Moxifloxacin, the active ingredient in Moxifloxacin Olikla, is a fluoroquinolone antibiotic presented as an oral tablet for systemic use. It targets susceptible Gram‑positive and Gram‑negative bacteria, providing treatment for adult patients with acute bacterial sinusitis, community‑acquired pneumonia, and skin and soft‑tissue infections.

GNH USA supplies Moxifloxacin Olikla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Moxifloxacin is indicated for bacterial infections affecting various organ systems.

- Acute Bacterial Sinusitis: reduces symptoms and eradicates the causative pathogens. - Community‑Acquired Bacterial Pneumonia: provides bactericidal activity against typical respiratory pathogens. - Acute Bacterial Exacerbation of Chronic Bronchitis: shortens the duration of exacerbation and improves lung function. - Skin and Skin Structure Infections: treats susceptible Gram‑positive and Gram‑negative organisms. - Complicated Intra‑Abdominal Infections (as part of combination therapy): covers mixed bacterial flora.

Moxifloxacin may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools, usually self‑limiting. - Headache: transient cranial discomfort. - Dizziness: occasional vertiginous sensations.

Serious or Rare Side Effects: - Tendon rupture or tendinitis: especially in the Achilles tendon. - QT interval prolongation: may precipitate cardiac arrhythmias. - Severe allergic reactions: including anaphylaxis and Stevens‑Johnson syndrome. - Clostridioides difficile‑associated colitis: can cause severe diarrhea and colitis.

When prescribing Moxifloxacin Olikla, clinicians should consider several safety factors.

- Renal or hepatic impairment: adjust therapy based on clinical judgment. - History of tendon disorders: avoid use or monitor closely for tendon pain. - QT prolongation risk: avoid in patients with known cardiac arrhythmias or electrolyte disturbances. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk to the fetus or infant. - Concomitant medications: review for potential interactions that may increase toxicity. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Moxifloxacin can interact with other medicines, requiring careful assessment.

Major Interactions (Avoid): - Systemic corticosteroids: increased risk of tendon rupture. - Other QT‑prolonging agents (e.g., macrolides, antiarrhythmics): additive cardiac risk. - Antacids or supplements containing aluminum, magnesium, calcium, iron, or zinc: significantly reduce oral absorption.

Moderate Interactions (Monitor Closely): - Warfarin: may potentiate anticoagulant effect; monitor INR. - Theophylline: may raise plasma levels; observe for toxicity.